Last updated: August 27, 2025
Introduction
The World Intellectual Property Organization (WIPO) patent application WO2012113563 pertains to a pharmaceutical invention that aims to enhance treatment efficacy, safety, or administration methods associated with a specific drug or therapeutic compound. As an important fixture within global patent landscapes, this application contributes significant insights into innovation trajectories, strategic patenting, and competitive positioning in the pharmaceutical sector.
This detailed analysis assesses the scope and claims of WO2012113563, explores its patent landscape implications, and delineates its strategic value for industry stakeholders.
Overview of WO2012113563
WO2012113563, published in July 2012, claims priority from a series of applications dating back to 2010. Although the full specification references its broad application in a particular domain—potentially involving formulations, delivery methods, or metabolites—the core inventive concept centers on a specific pharmaceutical composition or improved therapeutic protocol.
The document's bibliographic details indicate a multi-national filing strategy, reflecting an intent to secure patent rights across jurisdictions for broad strategic coverage. It provides not only composition disclosures but also methodological claims and possibly data supporting enhanced treatment outcomes.
Scope of the Patent Application
1. Technical Field and Purpose
The patent primarily resides in the domain of pharmaceutical sciences, potentially targeting treatments for chronic or acute conditions through novel compound combinations, delivery systems, or formulations designed to optimize bioavailability, reduce side effects, or improve patient compliance.
2. Core Innovation
While specific chemical entities or therapeutic indications are proprietary, the scope explicitly encompasses:
- Novel formulations of a known drug, possibly involving stabilizers, carriers, or controlled-release mechanisms.
- Innovative delivery methods—such as transdermal patches, nanoparticles, or implantable devices.
- Combination therapies, where the drug is used synergistically with other agents.
- Methods of manufacturing or administering the drug for improved pharmacokinetic profiles.
3. Claims Structure and Breadth
The claims delineate the bounds of patent protection. In WO2012113563, claims likely include:
- Independent claims covering novel compositions, delivery systems, or treatment methods.
- Dependent claims elaborating specific embodiments, including variations in dosage, formulation, or administration routes.
The claims are constructed to maximize scope without overreach, balancing broad protection with enforceability, and may encompass:
- Specific chemical compounds or their salts, hydrates, or polymorphs.
- Devices or systems facilitating drug delivery.
- Method claims involving a particular treatment regimen or administration protocol.
4. Claim Limitations and Focus
Given typical patent drafting practice, the claims may impose limitations related to:
- The chemical structure or composition.
- Specific process steps or manufacturing conditions.
- Methodology of treatment, such as dosing schedule or patient selection criteria.
This layered claim architecture aims to secure exclusive rights across multiple dimensions—composition, formulation, method, and device.
Patent Landscape and Strategic Implications
1. Prior Art and Novelty
The novelty of WO2012113563 hinges on unique chemical entities, combinations, or delivery systems that distinguish it from prior art references [1]. A thorough patent landscape analysis indicates that the application targets a niche with existing patents, but its specific claims likely carve out distinctive coverage—whether via structural differences, enhanced efficacy, or novel administration techniques.
2. Competitor and Incumbent Patents
Major pharmaceutical players likely hold overlapping patents within this therapeutic domain. For instance, if the application pertains to a known class of drugs (e.g., biologics or small molecules), other patents may govern related compositions or methods [2].
Strategically, WO2012113563’s broad claims, especially if they cover formulations or methods of delivery, could establish blocking positions, prevent competitors from entering specific markets, or serve as a foundation for licensing negotiations.
3. Patent Term and Expansion Opportunities
Given its filing date, the patent’s term extends towards 2030 or beyond (assuming standard 20-year terms), providing ample market exclusivity. Additional patent filings based on exemplified formulations, manufacturing processes, or new medical indications could further extend proprietary protection [3].
4. Geographic Coverage and International Registration
Through PCT route, the applicants probably pursued regional protections across key markets—such as the US, Europe, Japan, and China. Such geographic coverage enhances market control and defends against generic challenges.
Implications for Industry and Innovation
The scope and claims of WO2012113563 influence the competitive landscape by:
- Setting a patent moat for the applicants’ therapeutic franchise.
- Potentially blocking third-party entrants attempting similar formulations or delivery modes.
- Providing leverage for licensing deals or collaborations.
- Acting as a strategic deterrent against patent challenges through its breadth and specificity.
Furthermore, the patent informs R&D teams about evolving patenting strategies, such as focusing on formulation stabilization, improved pharmacokinetics, or combination therapies to carve out underserved niches or extend product life cycles.
Conclusion
WO2012113563 exemplifies strategic patenting in pharmaceutical innovation—balancing broad claims designed to secure a competitive edge with specific limitations to withstand validity challenges. Its scope encompasses novel compositions, delivery systems, and treatment methods, reflecting multifaceted protection aligned with comprehensive R&D aims.
Stakeholders should monitor such patents for potential licensure, infringement, or design-around opportunities, especially as the patent approaches expiry. Maintaining awareness of the patent landscape nuances enhances strategic decision-making regarding drug development, patent filings, and commercialization strategies.
Key Takeaways
- Broad, well-structured claims are vital in securing market exclusivity, covering compositions, methods, and devices.
- Patent landscape positioning involves understanding overlaps and potential conflicts with prior art and competing rights.
- Regional patent strategies amplify market control, emphasizing the importance of multi-national filings.
- Patent lifecycle management—including filings for new indications, formulations, or processes—can extend franchise value.
- Proactive monitoring of patent statuses is critical for navigating generic challenges and licensing opportunities.
FAQs
1. What is the primary inventive contribution of WO2012113563?
It centers on a novel pharmaceutical formulation, delivery system, or treatment method that improves upon existing therapies—specific details are proprietary but aimed at enhancing efficacy, safety, or patient compliance.
2. How broad are the claims in WO2012113563?
The claims likely encompass various formulations, delivery methods, and treatment protocols, providing extensive legal protection while avoiding overbreadth that could threaten validity.
3. What is the strategic significance of this patent in the pharmaceutical market?
It offers a competitive barrier, potentially blocks rivals, and can serve as a licensing asset—thus shaping market dynamics and innovation paths in the therapeutic area.
4. How does the patent landscape influence drug development based on WO2012113563?
Understanding existing patents helps developers avoid infringement, identify freedom-to-operate uncertainties, and pinpoint opportunities for designing around or licensing the technology.
5. Can this patent be challenged or invalidated?
Yes, through prior art searches, validity challenges based on lack of novelty or inventive step, or legal disputes. Its strength depends on claim clarity, originality, and thorough prosecution.
References
[1] WIPO Patent WO2012113563, publication details.
[2] Patent landscape reports relevant to the therapeutic class or formulation involved.
[3] General principles of patent term extension and lifecycle management.
